Form 4: MDGL EVP & CFO Reports Stock Grants and Planned Sales

Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals, Inc., reported the grant of restricted stock units and stock options, alongside sales of common stock, including tax-related sales and those under a 10b5-1 plan.

Summary

• Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals, Inc. (MDGL), reported several transactions involving the company's common stock.
• On March 4, 2026, Dier was granted 5,215 restricted stock units (RSUs) which will vest 25% annually starting March 4, 2027.
• Also on March 4, 2026, Dier was granted 6,519 stock options with an exercise price of $434.80, vesting 25% on March 4, 2027, and then 6.25% quarterly.
• On March 6, 2026, Dier sold 646 shares at $431.94 to cover tax withholding obligations related to RSU vesting. This sale was automatic.
• Additionally, on March 6, 2026, Dier sold a total of 1,982 shares (including the tax-related sale) through multiple transactions at weighted average prices ranging from $425.08 to $436.69. These sales were executed under a Rule 10b5-1 trading plan adopted on September 2, 2025.
• Following these transactions, Dier beneficially owns 12,490 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The grants of RSUs and stock options are positive for executive alignment, while the sales, though reducing direct ownership, were largely pre-planned and included tax-related obligations, mitigating negative sentiment.

Positives

• Grant of 5,215 restricted stock units (RSUs) to EVP and CFO Mardi Dier on March 4, 2026, aligning executive interests with long-term shareholder value.
• Grant of 6,519 stock options to EVP and CFO Mardi Dier on March 4, 2026, with an exercise price of $434.80, providing incentive for future stock price appreciation.

Negatives

• EVP and CFO Mardi Dier sold a total of 1,982 shares of common stock on March 6, 2026, reducing her direct beneficial ownership.
• The sales included 646 shares sold to cover tax withholding obligations, which, while automatic, represents a reduction in direct holdings.
• Additional sales of 1,306 shares were made under a pre-arranged Rule 10b5-1 trading plan, which can sometimes be perceived as a reduction in direct exposure, despite being planned.

Future Outlook

The restricted stock units (RSUs) are scheduled to vest 25% annually on March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030, contingent on continued service. The stock options will vest 25% on March 4, 2027, and then 6.25% on the last day of each successive three-month period, also contingent on continued service.

Industry Context

StockSavvy.ai notes that Form 4 filings provide transparency into executive compensation and insider trading activities, which are closely monitored by investors for signals regarding management's confidence in the company's future prospects. While these transactions are specific to an individual executive, the grants of equity compensation are a standard practice to align executive incentives with shareholder value in the biotechnology and pharmaceutical industry.

Related Party Transactions

• This filing details insider stock transactions, which are a form of related party dealing. However, it does not disclose other types of related party transactions (e.g., business dealings with entities owned by insiders).

Stakeholder Impact

• Shareholders: The grants of equity compensation can be seen as a positive signal for aligning executive interests with long-term shareholder value. The sales, while reducing direct ownership, were largely pre-planned, which may temper concerns about insider selling.
• Employees: The vesting schedules for RSUs and stock options are contingent on continued service, which can contribute to employee retention for the reporting person.

Next Steps

• Continued vesting of 5,215 restricted stock units, with 25% vesting annually on March 4, 2027, 2028, 2029, and 2030.
• Continued vesting of 6,519 stock options, with 25% vesting on March 4, 2027, and 6.25% quarterly thereafter.

Key Dates

Recommendation

The filing indicates standard executive compensation practices through RSU and stock option grants, which are generally positive for aligning management with shareholder interests. While there were sales of common stock, a significant portion was for tax obligations and the remainder was executed under a pre-arranged 10b5-1 plan, suggesting these are personal financial management actions rather than a reflection of a change in company fundamentals or outlook. Without additional information on company performance, the transactions themselves do not warrant a change from a 'hold' position.

Keywords

MDGL, Madrigal Pharmaceuticals, insider trading, Form 4, stock options, restricted stock units, 10b5-1 plan, executive compensation